CD8A and melanoma: CD8A exhibited good predictive performance, with 21 of 25 ICB-treated cohorts having an AUC greater than 0.5 (Figure 4C), among which two melanoma cohorts exhibited the strongest predictive likeliness for PD1 blockade.